ATE423133T1 - Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält - Google Patents

Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält

Info

Publication number
ATE423133T1
ATE423133T1 AT03780546T AT03780546T ATE423133T1 AT E423133 T1 ATE423133 T1 AT E423133T1 AT 03780546 T AT03780546 T AT 03780546T AT 03780546 T AT03780546 T AT 03780546T AT E423133 T1 ATE423133 T1 AT E423133T1
Authority
AT
Austria
Prior art keywords
amino acid
acid segment
materials
polypeptide containing
treating inflammation
Prior art date
Application number
AT03780546T
Other languages
English (en)
Inventor
Lars Hellman
Rikard Holmdahl
Original Assignee
Resistentia Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals Ab filed Critical Resistentia Pharmaceuticals Ab
Application granted granted Critical
Publication of ATE423133T1 publication Critical patent/ATE423133T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT03780546T 2002-12-02 2003-12-01 Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält ATE423133T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43027802P 2002-12-02 2002-12-02

Publications (1)

Publication Number Publication Date
ATE423133T1 true ATE423133T1 (de) 2009-03-15

Family

ID=32469435

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03780546T ATE423133T1 (de) 2002-12-02 2003-12-01 Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält

Country Status (15)

Country Link
US (2) US7361742B2 (de)
EP (1) EP1569958B1 (de)
JP (1) JP2006507834A (de)
KR (1) KR20050090390A (de)
CN (1) CN1745098A (de)
AT (1) ATE423133T1 (de)
AU (1) AU2003288472A1 (de)
CA (1) CA2508302A1 (de)
DE (1) DE60326264D1 (de)
ES (1) ES2323692T3 (de)
MX (1) MXPA05005909A (de)
NO (1) NO20052714L (de)
NZ (1) NZ540735A (de)
RU (1) RU2344144C2 (de)
WO (1) WO2004050111A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462325B2 (en) * 2001-11-30 2008-12-09 Nomadics, Inc. Luminescent polymer particles
RU2344144C2 (ru) * 2002-12-02 2009-01-20 Резистенция Фармасьютикалс Аб Способ лечения воспалительных состояний с помощью полипептида, содержащего собственные и чужеродные аминокислотные сегменты
PL1853305T3 (pl) * 2005-02-04 2015-02-27 Survac Aps Szczepionka na bazie peptydu surwiwina
US7858363B2 (en) * 2006-07-22 2010-12-28 Zymo Research Corporation Plasmid DNA isolation
KR100973428B1 (ko) 2008-05-19 2010-08-03 한국과학기술연구원 말토오스 결합 단백질을 이용한 생리활성 폴리펩타이드의고정화 방법
EP2468295A1 (de) * 2010-12-21 2012-06-27 Affiris AG Impfstoffe basierend auf Komplementprotein C5a Peptide
HUE041996T2 (hu) 2012-02-20 2019-07-29 Swedish Orphan Biovitrum Ab Publ A C5 humán komplementhez kötõdõ polipeptidek
US12320753B2 (en) * 2018-03-20 2025-06-03 Sanofi Pasteur Limited Methods for determining adjuvanted protein concentration and percent adsorption using intrinsic fluorescence

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
NO162210C (no) 1987-07-20 1989-11-22 Fasting Biotech As Monoklonale antistoffer mot c5a for in-vitro anvendelse ved immunologiske kvantitative teknikker eller ved isolering av c5a.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU6125096A (en) * 1995-06-05 1996-12-24 Novartis Ag C5a receptor antagonists having substantially no agonist activity and methods for preparation
DE69637571D1 (de) * 1995-10-20 2008-08-07 Univ Nebraska Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
ES2333775T3 (es) 2000-10-10 2010-03-01 Genentech, Inc. Inhibicion de la activacion del complemento c5 para el tratamiento y la prevencion de rechazo de xenoinjerto retrasado o rechazo vascular agudo.
WO2003015819A1 (en) 2001-08-17 2003-02-27 Tanox, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
RU2344144C2 (ru) * 2002-12-02 2009-01-20 Резистенция Фармасьютикалс Аб Способ лечения воспалительных состояний с помощью полипептида, содержащего собственные и чужеродные аминокислотные сегменты

Also Published As

Publication number Publication date
WO2004050111A3 (en) 2004-07-29
EP1569958A2 (de) 2005-09-07
US7361742B2 (en) 2008-04-22
NZ540735A (en) 2008-08-29
KR20050090390A (ko) 2005-09-13
RU2344144C2 (ru) 2009-01-20
EP1569958B1 (de) 2009-02-18
DE60326264D1 (de) 2009-04-02
JP2006507834A (ja) 2006-03-09
RU2005120785A (ru) 2006-01-20
ES2323692T3 (es) 2009-07-23
WO2004050111A2 (en) 2004-06-17
US20080262197A1 (en) 2008-10-23
NO20052714L (no) 2005-08-10
US20040214768A1 (en) 2004-10-28
CA2508302A1 (en) 2004-06-17
MXPA05005909A (es) 2005-08-26
CN1745098A (zh) 2006-03-08
NO20052714D0 (no) 2005-06-06
AU2003288472A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
RU2467016C2 (ru) Антитела к il-22 человека и их применение
CY1117702T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη
RU2007139452A (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ МОДУЛИРОВАНИЯ ГИПЕРСТАБИЛИЗИРОВАННОГО c-met
DE602005016818D1 (de) Verfahren zur charakterisierung einer polyklonalen zellinie
BRPI0612273A2 (pt) anticorpo de ligaÇço a il-1 beta ou fragmento de ligaÇço a il-1 beta do mesmo, Ácido nucleico, vetor, cÉlula, animal transgÊnico, hibridoma, composiÇço, e, mÉtodos de tratamento ou prevenÇço de uma doenÇa ou doenÇa relacionada a il-1 em um mamÍfero, e de preparaÇço de um polipeptÍdeo de ligaÇço a il-1 beta maturado por afinidade
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
ATE473294T1 (de) Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor
ATE423133T1 (de) Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält
ATE523523T1 (de) Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung
PE20100141A1 (es) Proteina de union al receptor de interleuquina 21
Ghosh et al. Differential expression of hyaluronic acid binding protein 1 (HABP1)/P32/C1QBP during progression of epidermal carcinoma
ATE474922T1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
MX2023005386A (es) Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina.
ATE469917T2 (de) Verfahren zur gewinnung von antikörpern
ATE509946T1 (de) Fluoreszenzproteine und chromoproteine aus nicht- aequorea-hydrozoa-spezies sowie verfahren zur verwendung davon
ATE428771T1 (de) Antikörper gegen hundepankreaslipase
ATE535546T1 (de) Humane monoklonale antikörper, die spezifisch an ifg-ii binden
DE50212790D1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
WO2005058362A3 (en) Method for opening tight junctions comprising the use of jam-1, claudin-4 and occludin protein antagonists as well as sirna molecules
Rossmann et al. Expression of serum amyloid A4 in human trophoblast-like choriocarcinoma cell lines and human first trimester/term trophoblast cells
DE602005022757D1 (de) Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen
WO2004096846A3 (en) Nogo-b, a regulator of endothelial cell function and vessel remodeling

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties